- Home
- OMCL vs VCEL Comparison
OMCL vs VCEL Comparison
Compare OMCL & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMCL | VCEL |
|---|---|---|
| Founded | 1992 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2000 | 1996 |
Fundamental Metrics
Financial Performance| Metric | OMCL | VCEL |
|---|---|---|
| Price | $40.71 | $37.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $51.14 | ★ $57.50 |
| AVG Volume (30 Days) | ★ 797.6K | 386.6K |
| Earning Date | 05-07-2026 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 160.00 | ★ 385.71 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $787,309,000.00 | $237,224,000.00 |
| Revenue This Year | $6.77 | $18.02 |
| Revenue Next Year | $4.82 | $18.52 |
| P/E Ratio | $446.11 | ★ N/A |
| Revenue Growth | 9.93 | ★ 20.10 |
| 52 Week Low | $22.66 | $29.24 |
| 52 Week High | $51.84 | $55.41 |
Technical Indicators
Market Signals| Indicator | OMCL | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 51.57 |
| Support Level | $28.61 | $34.61 |
| Resistance Level | $46.29 | $38.41 |
| Average True Range (ATR) | 2.02 | 1.60 |
| MACD | 0.25 | 0.28 |
| Stochastic Oscillator | 90.13 | 73.70 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.